A year after Flagship Pioneering updated its name to reflect the firm's investments in innovation and company creation, and revealed a new $285m special opportunities fund, it announced on Dec. 20 that it closed its largest fund to date totaling $618m.
Flagship has raised $2.3bn since it set up shop in 2000 and began putting money primarily into biopharmaceutical companies. It lists more than 35 portfolio companies, including both private firms and ventures that have moved from start-ups to publicly traded firms. Among them are private mRNA-focused Moderna Therapeutics LLC, the publicly traded microbiome dug developer Seres Therapeutics Inc. and the red blood cell-based therapeutics firm Rubius Therapeutics Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?